Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 6Tumor-Agnostic 5Gastrointestinal 5Breast 5Dermatologic 3Thoracic 2Head & Neck 2Gynecologic 2CNS 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Classical hematology 1

Conditions

Melanoma 3Skin Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 194aldesleukin 148Interleukin-2 110fludarabine phosphate 106trametinib 85Temozolomide 83Dacarbazine 81fludarabine 80dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Magnetic Resonance Spectroscopy 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Specimen Handling 47Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
reolysin × Dermatologic × Clear all
NCT03282188 2018-05-04

REO13 Melanoma With of Without GM-CSF

University of Leeds

Phase 1/2 Withdrawn
Dermatologic

Melanoma, Skin Neoplasms

NCT00984464 2015-04-10

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Oncolytics Biotech

Phase 2 Completed
14 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00651157 2014-04-22

Viral Therapy in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 6 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡